There is real evidence that timing changes the safety picture: hormone therapy started within about 10 years of menopause looks different, and generally safer, than starting it a decade or more later, especially for stroke and heart-related outcomes.

Whether early starting also actively protects the heart, versus simply being safer, is still debated. One purpose-built trial found early starters had slower thickening of the neck artery wall than those on placebo, a favorable but indirect signal, while another similarly designed trial found no difference in artery imaging at all. The honest summary is that timing clearly changes risk, but a proven heart-protective effect of early initiation has not been shown on hard outcomes like heart attacks or strokes in a randomized trial.

What to know about this answer

Whether the timing hypothesis is fully 'proven' splits the field. Supporters point to a trial designed specifically to test it that found the predicted pattern; skeptics point to a nearly identical trial that found nothing, and note the artery-imaging measurement used has repeatedly failed to reliably predict actual heart-attack or stroke reduction.

What the research shows, and which source each finding rests on

ELITE trial: 643 women stratified by years since menopause, randomized to oral estradiol vs placebo. In the early group (under 6 years since menopause), artery-wall thickening was 0.0044 mm/yr on estradiol vs 0.0078 mm/yr on placebo (p=0.008); in the late group (10+ years) there was no difference. The timing interaction was significant (p=0.007). Coronary CT scores showed no difference in either group.

B[1]

KEEPS trial: 727 recently menopausal women randomized to oral or transdermal estrogen vs placebo for 48 months found no difference in artery-wall thickening or coronary calcium progression between groups, though some risk markers improved.

B[2]

WHI age/timing gradient: coronary heart disease HR by years since menopause was 0.76 (under 10 years), 1.10 (10-19 years), and 1.28 (20+ years), p trend = 0.02; stroke risk was elevated regardless of timing (HR 1.32).

B[3]

DOPS trial: 1,006 women started hormone therapy about 7 months after menopause, 10 years of treatment, 16 years of follow-up: composite of death, heart failure admission, or heart attack HR 0.48 (0.26-0.87).

B[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Proven in substance

supporters including Dr. Hodis, Dr. Mack, and the WHI's own 2007 timing analysis

ELITE was designed prospectively to test the timing hypothesis and found exactly the predicted interaction (p=0.007) on artery-wall thickening; the WHI itself shows a trend across years-since-menopause (p=0.02); and animal models show estrogen slows early plaque formation but cannot reverse established plaque, consistent with a biological window.

B[1]B[3]

Only partially proven

skeptics, including many trialists

KEEPS, the other purpose-built early-window trial, found no difference in either artery-wall thickening or coronary calcium; ELITE's own coronary CT results were also null; artery-wall thickening is a surrogate measurement that has repeatedly failed to predict real event reduction in cardiology; and the WHI's age trend for coronary disease did not reach its own significance threshold, while stroke showed no timing window at all.

B[2]B[3]

What would settle it: The same large, long, hard-endpoint trial described in the heart-disease-prevention answer, or a validated way to link artery-wall thickening changes to actual event risk in this specific population.

What is really going on here

  1. Does that study apply to someone my age and my distance from menopause, or was it done in women 10-20 years older?
  2. Was the result I'm being told about an actual heart attack or stroke reduction, or a change in an artery-imaging measurement?

Questions for your doctor

  1. How many years am I from my last period, and does that change what's known about safety for me?
  2. Is the benefit you're describing based on an actual reduction in heart attacks or strokes, or an imaging measurement?
  3. What would change your recommendation if I were 10 years further from menopause?
  4. Is there a bigger trial planned or underway that could answer this more definitively?

Questions with no answer yet

Does slowing the thickening of the neck artery wall, the outcome one purpose-built trial found improved with early therapy, actually translate into fewer real heart attacks or strokes?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Artery-wall thickening is a surrogate imaging measurement, not an actual cardiovascular event. This kind of surrogate has repeatedly failed to reliably predict real event reduction elsewhere in cardiology, and no study has validated the specific link between this measurement and hard outcomes in this population.

What would test it: A validated method linking artery-wall-thickening changes to actual cardiovascular event risk in this specific population, or the large hard-endpoint trial described in the heart-disease-prevention question above.

Why did one purpose-built early-window trial find a timing effect on artery-wall thickening while a very similarly designed trial found no difference in either artery-wall thickening or coronary calcium?

Partly studied

What is known: Both trials were designed specifically to test the early window using imaging endpoints in recently menopausal women, yet one found a significant timing interaction and the other found no difference in either imaging measure. The reason for the discrepancy, whether trial design, population, or chance, has not been resolved.

What would test it: A larger trial or a formal meta-analysis pooling both imaging trials' raw data to see whether the disagreement reflects a real difference or falls within the range of chance variation.

Sources

  1. 1.Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.Hodis HN, Mack WJ, et al. Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). N Engl J Med. 2016;374(13):1221-31. · Randomised trial
  2. 2.Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.Harman SM, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women (KEEPS). Ann Intern Med. 2014;161(4):249-60. · Randomised trial
  3. 3.Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.Rossouw JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-77. · Randomised trial
  4. 4.Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial.Schierbeck LL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial (DOPS). BMJ. 2012;345:e6409. · Randomised trial

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions